Strategic Cooperation Framework Agreement With Chicmax In Relation To KT-939
Release time：2026-03-17 20:17
Suzhou, 17 March, 2026-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that Suzhou Kintor Pharmaceuticals, Inc. ( “ Suzhou Kintor ”), a wholly-owned subsidiary of the Company, entered into the exclusive strategic cooperation framework agreement (the “ Framework Agreement ”) in the cosmetics sector with Shanghai Chicmax Cosmetic Co., Ltd. (a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), “ Chicmax ”) in relation to the rapid commercialization of the Company’s whitening and freckle-removing functional cosmetic raw material KT-939.
Chicmax, a multi-brand beauty company listed on The Stock Exchange of Hong Kong Limited (stock code: 2145), focuses on research and development, manufacturing and sales of mass skin care, maternal, baby & teenagers skin care, cleansing and personal care, makeup, dermocosmetics and premium skin care.
With an operational history of more than 20 years, Chicmax has cultivated solid independent R&D capabilities and garnered comprehensive experience in multi-brand development and operations within China ’ s cosmetics industry, with strong dual R&D capabilities and talents, combined with an extensive and dynamic sales and distribution network. Its dedication to continuous innovation in marketing strategies, robust brand power, exceptional supply chain management, and experienced team has enabled it to successfully create a diverse array of popular cosmetics brands, including multiple well-known brands such as KANS, newpage, ARMIYO, and Baby Elephant.
Pursuant to the Framework Agreement, Suzhou Kintor and Chicmax will exclusively collaborate in the cosmetics sector on the registration of KT-939 as a new cosmetic ingredient and the registration of cosmetic products with KT-939 as the main ingredient , and jointly conduct the R&D and customization of functional raw materials with an aim to position KT-939 as the " ultimate domestic whitening agent " with prominent industry influence.
The exclusive Framework Agreement in the cosmetics sector with Chicmax is based on the high complementarity of resources and strategic synergy to each other in the cosmetics and biopharmaceutical fields, aiming to fully leverage the premium resources and capabilities of both parties to jointly explore the market and realize win-win values.
As an R&D-driven leader in the multi-brand cosmetics industry , Chicmax possesses strong brand operation and market commercialization capabilities. Suzhou Kintor, with its core focus on innovative drug research and development, has built a solid foundation in raw material research and development and technological expertise. Through this collaboration, both parties will not only accelerate the commercialization process of KT-939, enabling the simultaneous launch of the cosmetic ingredient and products, but also foster synergies in technology sharing, intellectual property protection, and market promotion. This will further enhance the technological sophistication and market competitiveness of domestic whitening ingredients, ultimately achieving the strategic goals of mutual benefits and development.
Previous:
recommend News
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn